Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the male or female breast (male or female) with gross, uncontrolled, unresectable breast and/or chest wall disease including: 1. patients with locally advanced unresectable stage IIIa or IIIb; 2. patients with locally recurrent (including locoregional lymph nodes) disease for which curative surgery is not thought possible 3. patients with metastatic disease AND uncontrolled locoregional disease are eligible. * Prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or high dose chemotherapy with marrow or stem cell rescue. * Prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung) * 4 weeks since any prior treatments (excluding hormonal therapy). Concurrent hormonal therapy is not allowed. * Aged 18 years or older * CALGB performance status of 0 - 2 * Life expectance of at least 12 weeks * Initial Laboratory Data: * ANC Count \> 1500/mm3 * Platelet Count \> 100,000/mm3 * Creatine ≤ 2.0 mg/dl * Bilirubin ≤ 1.5 mg/dl * ALT (SGPT) ≤ 3 times the upper limit of normal * Signed informed consent Exclusion Criteria: * Prior breast or chest wall radiation is not allowed unless the proposed site radiation port does not overlap with prior ports * Subjects must not be pregnant (females able to have children must have negative pregnancy test and agree to use adequate contraception) * Patients with a documented hypersensitivity to E.coli derived proteins are excluded. * No other serious medical condition such as uncontrolled infection that in the opinion of the investigators places patient at undue risk for study treatment